Gilead Receives FDA Approval for Chronic HDV Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 39 minutes ago
0mins
Source: Newsfilter
- FDA Accelerated Approval: Gilead Sciences announced that its Hepcludex (bulevirtide-gmod) 8.5 mg has received accelerated approval from the FDA, becoming the first treatment for chronic hepatitis delta virus (HDV) infection in the U.S., addressing a significant unmet medical need.
- Clinical Trial Results: In the pivotal MYR301 Phase 3 trial, Hepcludex demonstrated statistically significant improvements in HDV RNA reduction and alanine aminotransferase (ALT) normalization at Week 48 compared to the control group, indicating its efficacy.
- Patient Impact: Chronic HDV is considered the most severe form of viral hepatitis, and the FDA approval provides a new treatment option for approximately 40,000 to 80,000 HDV patients in the U.S., potentially significantly improving their quality of life and disease management.
- Future Research Commitment: Gilead has committed to conducting a confirmatory long-term outcomes study to verify the clinical benefits of Hepcludex, ensuring continued approval, which reflects the company's strong commitment to addressing this serious disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 130.500
Low
105.00
Averages
137.88
High
154.00
Current: 130.500
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. It operates in over 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
WHO Raises Ebola Outbreak Risk Level in DRC to Very High
- Risk Level Increase: The WHO has raised the risk assessment for the Bundibugyo Ebola strain in the Democratic Republic of Congo to 'very high', indicating a significant potential for rapid virus spread that threatens national public health.
- Case Statistics: Currently, 82 confirmed Ebola cases have been reported in Congo, with 7 deaths, 177 suspected deaths, and nearly 750 suspected cases, highlighting the severity and transmission potential of the outbreak.
- Uganda's Control Measures: Uganda has implemented measures such as intense contact tracing and cancellation of mass gatherings, which have effectively contained the virus's spread, despite two confirmed cases from Congo, one of which was fatal.
- Experimental Treatment Options: The WHO mentioned that Gilead Sciences' experimental antiviral drug Obeldesivir could be used among Ebola contacts for preventive treatment, although its implementation must follow very strict protocols, offering hope in the fight against the outbreak.
See More
Gilead Secures Accelerated Approval for Hepcludex
- FDA Accelerated Approval: Gilead Sciences' Hepcludex has received accelerated approval from the FDA, becoming the first treatment for chronic hepatitis delta virus infection in the U.S., addressing a long-standing gap in care for approximately 40,000 to 80,000 patients, which is expected to significantly enhance their quality of life.
- Clinical Trial Data Support: The FDA's decision was heavily informed by data from the MYR301 multi-center Phase 3 clinical trial, which demonstrated that the percentage of participants with completely undetectable viral levels increased from 20% at week 48 to 50% by week 144, confirming the drug's efficacy over time.
- Positive Market Reaction: Following the FDA approval, Gilead's stock price surged nearly 3%, poised for its best day in about three months, reflecting strong market anticipation for the new therapy and a recovery in investor confidence, with a 29% increase in stock price over the past year.
- Global Market Presence: While newly approved in the U.S., the 2 mg dose of Hepcludex has already been available in the European Economic Area and other global markets, indicating Gilead's strategic positioning and commitment to addressing chronic liver disease treatment worldwide.
See More
Gilead Receives FDA Approval for Chronic HDV Treatment
- FDA Accelerated Approval: Gilead Sciences announced that its Hepcludex (bulevirtide-gmod) 8.5 mg has received accelerated approval from the FDA, becoming the first treatment for chronic hepatitis delta virus (HDV) infection in the U.S., addressing a significant unmet medical need.
- Clinical Trial Results: In the pivotal MYR301 Phase 3 trial, Hepcludex demonstrated statistically significant improvements in HDV RNA reduction and alanine aminotransferase (ALT) normalization at Week 48 compared to the control group, indicating its efficacy.
- Patient Impact: Chronic HDV is considered the most severe form of viral hepatitis, and the FDA approval provides a new treatment option for approximately 40,000 to 80,000 HDV patients in the U.S., potentially significantly improving their quality of life and disease management.
- Future Research Commitment: Gilead has committed to conducting a confirmatory long-term outcomes study to verify the clinical benefits of Hepcludex, ensuring continued approval, which reflects the company's strong commitment to addressing this serious disease.
See More
FDA Approves Gilead's Hepcludex for HDV Infection
- First HDV Treatment: Gilead Sciences' Hepcludex (bulevirtide) has received FDA approval as the first-ever therapy for chronic hepatitis delta virus (HDV) infection, marking a significant breakthrough in liver disease treatment.
- Clinical Trial Success: The approval is based on phase 3 trial results showing that patients receiving Hepcludex had significantly better combined responses compared to those receiving delayed treatment, indicating its clinical efficacy.
- Special Drug Designations: Hepcludex has received Breakthrough Therapy and Orphan Drug designations, which not only expedited its approval process but also reflects the FDA's recognition of its potential in treating HDV infections.
- International Market Outlook: Approved in the EU in 2020 and expected to launch in Canada in 2025, Hepcludex demonstrates broad application potential in global markets, which could lead to substantial revenue growth for Gilead.
See More
Trodelvy Recommended for First-Line Treatment in Europe
- EU Recommendation: Gilead Sciences announced that the European Medicines Agency's Committee recommended Trodelvy as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, with a decision from the European Commission expected later this year, which could significantly enhance the company's position in the oncology market.
- Clinical Trial Data: This recommendation is based on data from the ASCENT-03 study, which demonstrated statistically significant and clinically meaningful progression-free survival benefits for Trodelvy compared to standard chemotherapy, thereby increasing physician confidence and market acceptance of the drug.
- US Application: Gilead has also submitted an application to the U.S. Food and Drug Administration seeking approval for Trodelvy, aiming to expand its indications in the U.S. market, which, if approved, will further solidify its competitive edge globally.
- Combination Therapy Applications: Additionally, the company has submitted supplemental applications to the EMA and FDA for Trodelvy in combination with Keytruda for patients with PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer, a strategy that will help broaden its indication range and enhance market share.
See More
Gilead Completes Acquisition of Tubulis to Enhance Oncology Leadership
- Acquisition Scale: Gilead has completed the acquisition of Tubulis for $3.15 billion in cash, with potential milestone payments of up to $1.85 billion, aimed at enhancing its competitive edge in antibody-drug conjugate (ADC) technology and driving innovation in cancer treatment.
- Technological Integration: Tubulis' ADC technology boasts superior biophysical properties that enable more precise drug delivery, particularly with its lead asset TUB-040 showing promising anti-tumor activity in platinum-resistant ovarian cancer patients, which is expected to significantly diversify Gilead's treatment options.
- Innovation Center Establishment: Post-acquisition, the Tubulis team will continue operations in Munich, Germany, establishing the Tubulis ADC Innovation Center focused on integrating discovery, manufacturing, and clinical capabilities to accelerate the development of next-generation ADCs, further solidifying Gilead's leadership in oncology.
- Future Growth Potential: Gilead plans to invest $32 billion by 2025 to strengthen its U.S. operations, and the acquisition of Tubulis is expected to inject new momentum into its oncology product line, helping the company address significant challenges in cancer treatment globally.
See More
WHO Raises Ebola Outbreak Risk Level in DRC to Very High
- Risk Level Increase: The WHO has raised the risk assessment for the Bundibugyo Ebola strain in the Democratic Republic of Congo to 'very high', indicating a significant potential for rapid virus spread that threatens national public health.
- Case Statistics: Currently, 82 confirmed Ebola cases have been reported in Congo, with 7 deaths, 177 suspected deaths, and nearly 750 suspected cases, highlighting the severity and transmission potential of the outbreak.
- Uganda's Control Measures: Uganda has implemented measures such as intense contact tracing and cancellation of mass gatherings, which have effectively contained the virus's spread, despite two confirmed cases from Congo, one of which was fatal.
- Experimental Treatment Options: The WHO mentioned that Gilead Sciences' experimental antiviral drug Obeldesivir could be used among Ebola contacts for preventive treatment, although its implementation must follow very strict protocols, offering hope in the fight against the outbreak.
See More
Gilead Secures Accelerated Approval for Hepcludex
- FDA Accelerated Approval: Gilead Sciences' Hepcludex has received accelerated approval from the FDA, becoming the first treatment for chronic hepatitis delta virus infection in the U.S., addressing a long-standing gap in care for approximately 40,000 to 80,000 patients, which is expected to significantly enhance their quality of life.
- Clinical Trial Data Support: The FDA's decision was heavily informed by data from the MYR301 multi-center Phase 3 clinical trial, which demonstrated that the percentage of participants with completely undetectable viral levels increased from 20% at week 48 to 50% by week 144, confirming the drug's efficacy over time.
- Positive Market Reaction: Following the FDA approval, Gilead's stock price surged nearly 3%, poised for its best day in about three months, reflecting strong market anticipation for the new therapy and a recovery in investor confidence, with a 29% increase in stock price over the past year.
- Global Market Presence: While newly approved in the U.S., the 2 mg dose of Hepcludex has already been available in the European Economic Area and other global markets, indicating Gilead's strategic positioning and commitment to addressing chronic liver disease treatment worldwide.
See More
Gilead Receives FDA Approval for Chronic HDV Treatment
- FDA Accelerated Approval: Gilead Sciences announced that its Hepcludex (bulevirtide-gmod) 8.5 mg has received accelerated approval from the FDA, becoming the first treatment for chronic hepatitis delta virus (HDV) infection in the U.S., addressing a significant unmet medical need.
- Clinical Trial Results: In the pivotal MYR301 Phase 3 trial, Hepcludex demonstrated statistically significant improvements in HDV RNA reduction and alanine aminotransferase (ALT) normalization at Week 48 compared to the control group, indicating its efficacy.
- Patient Impact: Chronic HDV is considered the most severe form of viral hepatitis, and the FDA approval provides a new treatment option for approximately 40,000 to 80,000 HDV patients in the U.S., potentially significantly improving their quality of life and disease management.
- Future Research Commitment: Gilead has committed to conducting a confirmatory long-term outcomes study to verify the clinical benefits of Hepcludex, ensuring continued approval, which reflects the company's strong commitment to addressing this serious disease.
See More
FDA Approves Gilead's Hepcludex for HDV Infection
- First HDV Treatment: Gilead Sciences' Hepcludex (bulevirtide) has received FDA approval as the first-ever therapy for chronic hepatitis delta virus (HDV) infection, marking a significant breakthrough in liver disease treatment.
- Clinical Trial Success: The approval is based on phase 3 trial results showing that patients receiving Hepcludex had significantly better combined responses compared to those receiving delayed treatment, indicating its clinical efficacy.
- Special Drug Designations: Hepcludex has received Breakthrough Therapy and Orphan Drug designations, which not only expedited its approval process but also reflects the FDA's recognition of its potential in treating HDV infections.
- International Market Outlook: Approved in the EU in 2020 and expected to launch in Canada in 2025, Hepcludex demonstrates broad application potential in global markets, which could lead to substantial revenue growth for Gilead.
See More
Trodelvy Recommended for First-Line Treatment in Europe
- EU Recommendation: Gilead Sciences announced that the European Medicines Agency's Committee recommended Trodelvy as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, with a decision from the European Commission expected later this year, which could significantly enhance the company's position in the oncology market.
- Clinical Trial Data: This recommendation is based on data from the ASCENT-03 study, which demonstrated statistically significant and clinically meaningful progression-free survival benefits for Trodelvy compared to standard chemotherapy, thereby increasing physician confidence and market acceptance of the drug.
- US Application: Gilead has also submitted an application to the U.S. Food and Drug Administration seeking approval for Trodelvy, aiming to expand its indications in the U.S. market, which, if approved, will further solidify its competitive edge globally.
- Combination Therapy Applications: Additionally, the company has submitted supplemental applications to the EMA and FDA for Trodelvy in combination with Keytruda for patients with PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer, a strategy that will help broaden its indication range and enhance market share.
See More
Gilead Completes Acquisition of Tubulis to Enhance Oncology Leadership
- Acquisition Scale: Gilead has completed the acquisition of Tubulis for $3.15 billion in cash, with potential milestone payments of up to $1.85 billion, aimed at enhancing its competitive edge in antibody-drug conjugate (ADC) technology and driving innovation in cancer treatment.
- Technological Integration: Tubulis' ADC technology boasts superior biophysical properties that enable more precise drug delivery, particularly with its lead asset TUB-040 showing promising anti-tumor activity in platinum-resistant ovarian cancer patients, which is expected to significantly diversify Gilead's treatment options.
- Innovation Center Establishment: Post-acquisition, the Tubulis team will continue operations in Munich, Germany, establishing the Tubulis ADC Innovation Center focused on integrating discovery, manufacturing, and clinical capabilities to accelerate the development of next-generation ADCs, further solidifying Gilead's leadership in oncology.
- Future Growth Potential: Gilead plans to invest $32 billion by 2025 to strengthen its U.S. operations, and the acquisition of Tubulis is expected to inject new momentum into its oncology product line, helping the company address significant challenges in cancer treatment globally.
See More
